QURE

uniQure N.V.
CAPPED RATING

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure N.V. (QURE) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Revisions (F). The rating has held at C- for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C
Factor Score 2.5 / 5.0
Growth
B+
Factor Score 3.6 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
D+
Factor Score 1.6 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -8.0
EV / EBITDA -8.5
Rev Growth YoY 40.4%
Gross Margin 0.0%
Price Return 3M -50.4%
Price Return 12M -20.9%
Catalyst Signal 0.00
Market Cap $1.7B
TTM Revenue $20.2M
Price / Sales 82.8
ROE -89.0%

Historical Factor Score Progression

Held C- for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C (2.5) B+ (3.6) C- (2.1) D+ (1.6) F (0.0) C- (2.0)
2026-11-07 C+ (2.5) B (3.3) C- (2.0) D+ (1.6) F (0.0) C- (1.9)
2026-10-31 C (2.4) B (3.3) C- (2.1) C- (2.0) F (0.0) C- (2.0)
2026-10-24 C (2.5) B (3.3) C- (2.1) C+ (2.6) C+ (2.6) C+ (2.6)
2026-10-17 C+ (2.5) B (3.3) C- (2.1) C+ (2.7) C+ (2.6) C+ (2.6)
Page 1 of 5